Targeted Next-Generation Sequencing Identified Novel Mutations in Triple-Negative Myeloproliferative Neoplasms
Mutations in JAK2, MPL and CALR genes have been identified in the majority of patients with myeloproliferative neoplasms (MPNs), and patients negative for these three mutations are the so-called triple-negative (TN) MPNs. In this study, the researchers found that both somatic and germline mutations may be detected in TN MPN patients.
Med Oncol
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology